# Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

> **NCT00164892** · PHASE3 · UNKNOWN · sponsor: **Chinese University of Hong Kong** · enrollment: 214 (—)

## Conditions studied

- Cancer of Stomach

## Interventions

- **DRUG:** Oral Vioxx (Rofecoxib)

## Key facts

- **NCT ID:** NCT00164892
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 214 (—)
- **Last updated:** 2005-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00164892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00164892, "Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00164892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*